Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 13 | 2021 | 246 | 3.420 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 88 | 1.970 |
Why?
|
| Hyponatremia | 3 | 2023 | 9 | 1.960 |
Why?
|
| Child | 24 | 2023 | 1420 | 1.640 |
Why?
|
| Kidney Failure, Chronic | 4 | 2019 | 165 | 1.500 |
Why?
|
| Sodium | 5 | 2023 | 64 | 1.460 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 47 | 1.410 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 26 | 1.130 |
Why?
|
| Hypercalcemia | 2 | 2022 | 11 | 1.110 |
Why?
|
| Humans | 49 | 2023 | 28436 | 1.090 |
Why?
|
| Adolescent | 20 | 2021 | 2307 | 1.090 |
Why?
|
| Hydronephrosis | 2 | 2019 | 9 | 1.070 |
Why?
|
| Alkalosis | 2 | 2023 | 2 | 1.050 |
Why?
|
| Allopurinol | 2 | 2018 | 5 | 1.050 |
Why?
|
| Hyperkalemia | 2 | 2022 | 6 | 1.050 |
Why?
|
| Potassium | 3 | 2022 | 66 | 1.010 |
Why?
|
| Albuminuria | 4 | 2007 | 14 | 1.010 |
Why?
|
| Uric Acid | 3 | 2020 | 15 | 0.980 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 24 | 0.950 |
Why?
|
| Dyslipidemias | 2 | 2021 | 18 | 0.920 |
Why?
|
| Child, Preschool | 10 | 2022 | 688 | 0.890 |
Why?
|
| Antihypertensive Agents | 5 | 2019 | 81 | 0.870 |
Why?
|
| Alkalosis, Respiratory | 1 | 2023 | 1 | 0.850 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2007 | 25 | 0.850 |
Why?
|
| Acidosis | 1 | 2023 | 5 | 0.840 |
Why?
|
| Prospective Studies | 11 | 2023 | 1809 | 0.840 |
Why?
|
| Renin-Angiotensin System | 2 | 2021 | 5 | 0.830 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 53 | 0.830 |
Why?
|
| Cyclosporine | 1 | 2022 | 13 | 0.810 |
Why?
|
| Kidney Transplantation | 3 | 2013 | 133 | 0.800 |
Why?
|
| Urine | 2 | 2019 | 9 | 0.790 |
Why?
|
| Ureteral Obstruction | 2 | 2019 | 21 | 0.760 |
Why?
|
| Male | 26 | 2022 | 15291 | 0.740 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 1 | 0.720 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2020 | 2 | 0.720 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 2 | 0.720 |
Why?
|
| Biomarkers | 4 | 2019 | 596 | 0.720 |
Why?
|
| Smoking Cessation | 1 | 2021 | 48 | 0.710 |
Why?
|
| Cerebrum | 1 | 2020 | 11 | 0.710 |
Why?
|
| Hyperuricemia | 2 | 2018 | 4 | 0.700 |
Why?
|
| Female | 24 | 2022 | 15730 | 0.690 |
Why?
|
| Polyomavirus | 1 | 2019 | 6 | 0.670 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 17 | 0.660 |
Why?
|
| Kidney | 2 | 2018 | 175 | 0.650 |
Why?
|
| Risk Factors | 10 | 2021 | 2408 | 0.650 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2019 | 1 | 0.640 |
Why?
|
| Shock | 1 | 2019 | 11 | 0.630 |
Why?
|
| Obesity | 1 | 2021 | 321 | 0.610 |
Why?
|
| Creatinine | 5 | 2021 | 53 | 0.600 |
Why?
|
| Infant | 7 | 2021 | 587 | 0.590 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 104 | 0.550 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 7 | 0.510 |
Why?
|
| Hemofiltration | 1 | 2016 | 8 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 11 | 0.510 |
Why?
|
| Hypokalemia | 2 | 2008 | 4 | 0.510 |
Why?
|
| Enalapril | 2 | 2019 | 4 | 0.490 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 4 | 0.480 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 11 | 0.480 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2015 | 3 | 0.480 |
Why?
|
| Algorithms | 3 | 2012 | 377 | 0.480 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 196 | 0.460 |
Why?
|
| Antimetabolites | 1 | 2013 | 13 | 0.440 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2019 | 2 | 0.430 |
Why?
|
| Acetazolamide | 2 | 2019 | 3 | 0.430 |
Why?
|
| Critical Care | 1 | 2016 | 199 | 0.430 |
Why?
|
| Pediatrics | 1 | 2013 | 46 | 0.420 |
Why?
|
| Kidney Diseases | 2 | 2006 | 109 | 0.420 |
Why?
|
| Physician's Role | 1 | 2013 | 19 | 0.410 |
Why?
|
| Gout | 1 | 2012 | 7 | 0.410 |
Why?
|
| Infant, Newborn | 5 | 2019 | 654 | 0.400 |
Why?
|
| Fluid Therapy | 3 | 2012 | 34 | 0.390 |
Why?
|
| Behavior Therapy | 2 | 2023 | 91 | 0.370 |
Why?
|
| Adult | 9 | 2023 | 8107 | 0.370 |
Why?
|
| Disease Progression | 4 | 2019 | 717 | 0.370 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 2 | 0.360 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 7 | 0.360 |
Why?
|
| Placenta | 1 | 2010 | 10 | 0.360 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 1 | 0.350 |
Why?
|
| Critical Illness | 3 | 2023 | 135 | 0.350 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 68 | 0.350 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 933 | 0.340 |
Why?
|
| Blood Pressure | 6 | 2020 | 208 | 0.340 |
Why?
|
| Magnesium Deficiency | 1 | 2010 | 1 | 0.340 |
Why?
|
| Gitelman Syndrome | 1 | 2010 | 1 | 0.340 |
Why?
|
| Magnesium | 1 | 2010 | 36 | 0.330 |
Why?
|
| Cytokines | 1 | 2010 | 230 | 0.320 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 20 | 0.310 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2008 | 5 | 0.310 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2008 | 2 | 0.310 |
Why?
|
| Catecholamines | 1 | 2008 | 9 | 0.310 |
Why?
|
| Acid-Base Imbalance | 1 | 2008 | 3 | 0.310 |
Why?
|
| Transfusion Reaction | 1 | 2008 | 7 | 0.310 |
Why?
|
| Young Adult | 3 | 2021 | 2069 | 0.310 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3615 | 0.290 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 25 | 0.270 |
Why?
|
| Cerebellum | 1 | 2007 | 46 | 0.270 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2006 | 2 | 0.260 |
Why?
|
| Premedication | 1 | 2006 | 3 | 0.260 |
Why?
|
| Rett Syndrome | 1 | 2006 | 6 | 0.260 |
Why?
|
| Pregnancy | 2 | 2021 | 342 | 0.260 |
Why?
|
| Transcription Factors | 1 | 2007 | 172 | 0.250 |
Why?
|
| Contrast Media | 1 | 2006 | 75 | 0.250 |
Why?
|
| Nail Diseases | 1 | 2005 | 1 | 0.250 |
Why?
|
| Strontium | 1 | 2005 | 2 | 0.250 |
Why?
|
| Hematuria | 1 | 2005 | 16 | 0.250 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 48 | 0.240 |
Why?
|
| Autonomic Dysreflexia | 1 | 2004 | 2 | 0.240 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2004 | 5 | 0.230 |
Why?
|
| Down Syndrome | 1 | 2004 | 10 | 0.230 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 95 | 0.220 |
Why?
|
| Diarrhea | 1 | 2003 | 33 | 0.220 |
Why?
|
| Hyperventilation | 1 | 2023 | 1 | 0.210 |
Why?
|
| Bicarbonates | 1 | 2023 | 3 | 0.210 |
Why?
|
| Acid-Base Equilibrium | 1 | 2023 | 7 | 0.210 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 7 | 0.210 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 11 | 0.210 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 372 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 15 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2023 | 149 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 30 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 34 | 0.200 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cystinosis | 1 | 2002 | 1 | 0.200 |
Why?
|
| Failure to Thrive | 1 | 2002 | 2 | 0.200 |
Why?
|
| Constipation | 1 | 2002 | 19 | 0.200 |
Why?
|
| Steroids | 1 | 2022 | 26 | 0.200 |
Why?
|
| Rituximab | 1 | 2022 | 49 | 0.200 |
Why?
|
| ROC Curve | 2 | 2020 | 144 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 120 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 7 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2021 | 465 | 0.190 |
Why?
|
| Colistin | 1 | 2021 | 4 | 0.190 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 28 | 0.190 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 73 | 0.190 |
Why?
|
| Electrocardiography | 1 | 2022 | 119 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 140 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2022 | 123 | 0.180 |
Why?
|
| Body Size | 1 | 2020 | 13 | 0.170 |
Why?
|
| Diuretics | 3 | 2019 | 6 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2019 | 677 | 0.170 |
Why?
|
| Bartter Syndrome | 1 | 2019 | 1 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 80 | 0.160 |
Why?
|
| Interleukin-18 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Lipocalin-2 | 1 | 2019 | 2 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 62 | 0.160 |
Why?
|
| Calcium | 1 | 2022 | 381 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 492 | 0.150 |
Why?
|
| Age Factors | 2 | 2013 | 781 | 0.150 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 49 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 183 | 0.150 |
Why?
|
| Radiography | 2 | 2012 | 640 | 0.140 |
Why?
|
| Prevalence | 1 | 2019 | 468 | 0.140 |
Why?
|
| Pharmacokinetics | 1 | 2016 | 3 | 0.130 |
Why?
|
| Iran | 3 | 2020 | 32 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 23 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 205 | 0.120 |
Why?
|
| Cyclic GMP | 1 | 2015 | 6 | 0.120 |
Why?
|
| Aquaporin 2 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 20 | 0.120 |
Why?
|
| Urinalysis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2013 | 40 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2013 | 23 | 0.100 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Urethral Obstruction | 1 | 2012 | 1 | 0.100 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2012 | 6 | 0.100 |
Why?
|
| Syndrome | 2 | 2003 | 82 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 43 | 0.100 |
Why?
|
| Urethra | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 28 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2012 | 22 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2012 | 67 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2012 | 102 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 160 | 0.090 |
Why?
|
| Spironolactone | 2 | 2019 | 2 | 0.090 |
Why?
|
| Fetal Blood | 1 | 2010 | 13 | 0.090 |
Why?
|
| Patient Selection | 1 | 2012 | 206 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 56 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 2010 | 40 | 0.090 |
Why?
|
| Calcitriol | 1 | 2010 | 4 | 0.090 |
Why?
|
| Life Style | 1 | 2012 | 201 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2010 | 79 | 0.090 |
Why?
|
| Vitamins | 1 | 2010 | 21 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 166 | 0.090 |
Why?
|
| Phosphates | 1 | 2010 | 22 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 141 | 0.090 |
Why?
|
| Problem Solving | 1 | 2010 | 47 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 192 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 36 | 0.080 |
Why?
|
| Furosemide | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 6 | 0.080 |
Why?
|
| Renin | 1 | 2008 | 1 | 0.080 |
Why?
|
| Electroretinography | 1 | 2007 | 1 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Blindness | 1 | 2007 | 12 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 120 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 266 | 0.070 |
Why?
|
| Neoplasms | 1 | 2009 | 239 | 0.060 |
Why?
|
| Water Supply | 1 | 2005 | 4 | 0.060 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2005 | 9 | 0.060 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Labetalol | 1 | 2004 | 6 | 0.060 |
Why?
|
| Glomerular Mesangium | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 50 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 38 | 0.060 |
Why?
|
| Dehydration | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2009 | 1926 | 0.050 |
Why?
|
| Microcephaly | 1 | 2003 | 1 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2003 | 1 | 0.050 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2003 | 3 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cryptorchidism | 1 | 2003 | 4 | 0.050 |
Why?
|
| Ligases | 1 | 2003 | 10 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 11 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 8 | 0.050 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2003 | 6 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 25 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2003 | 26 | 0.050 |
Why?
|
| Glycine | 1 | 2003 | 12 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 26 | 0.050 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2002 | 2 | 0.050 |
Why?
|
| Amiloride | 1 | 2002 | 5 | 0.050 |
Why?
|
| Electrolytes | 1 | 2002 | 13 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 22 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 53 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 44 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 129 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 1143 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2020 | 14 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2020 | 6 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 35 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 243 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 441 | 0.040 |
Why?
|
| Body Height | 1 | 2020 | 36 | 0.040 |
Why?
|
| Indomethacin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 27 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3612 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 383 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 476 | 0.040 |
Why?
|